Regeneron's blockbuster eye drug posts weaker sales due to inventory impact | Business Information & News | Westlaw

Regeneron's blockbuster eye drug posts weaker sales due to inventory impact | Business Information & News | Westlaw

View on Westlaw or start a FREE TRIAL today, Regeneron's blockbuster eye drug posts weaker sales due to inventory impact, Business Information & News
5/2/24 REUTERS 10:39:30
REUTERS
Copyright (c) 2024 Thomson Reuters
May 2, 2024
Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Sriparna Roy; Bengaluru
Shailesh Kuber
(Reuters) -U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for quarterly profit on Thursday, hurt by softer sales of its blockbuster eye drug Eylea due to reduction in wholesaler inventory.
Apart from an impact of about $40...
---- Index References ----
Company: REGENERON PHARMACEUTICALS, INC.
News Subject: (Broker Recommendations (1BR58); Business Management (1BU42); Corporate Events (1CR05); Corporate Financial Data (1XO59); Equity Instruments (1EQ90); Funding Instruments (1FU41); Inventory (1IN48); Purchasing Management (1PU93); Stock Markets (1ST45))
Industry: (Financial Services (1FI37); Investment Management (1IN34); Pharmaceuticals & Biotechnology (1PH13); Securities Investment (1SE57))
Language: EN
Other Indexing: (Regeneron Pharmaceuticals Inc)
Keywords: health
Word Count: 295
End of Document© 2024 Thomson Reuters. No claim to original U.S. Government Works.